Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.

Autor: Huang F; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Voelk C; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Trampisch M; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany., Rowland L; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Schultz A; CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany., Sabo JP; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Jazyk: angličtina
Zdroj: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2018 Jul; Vol. 123 (1), pp. 84-93. Date of Electronic Publication: 2018 Mar 30.
DOI: 10.1111/bcpt.12980
Abstrakt: Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus. In this single-centre, open-label, fixed-sequence, crossover study of 32 healthy adult male and female volunteers, subjects received either a single dose of cyclosporine (CsA) 50 mg (N = 16) or tacrolimus (TAC) 0.5 mg (N = 16), followed by a washout of at least 14 days. Each subject then received a loading dose of FDV 240 mg followed by 120 mg FDV once daily for 6 days. FDV 120 mg was then co-administered with an additional single dose of CsA (50 mg) or TAC (0.5 mg), followed by an additional 6 days of FDV 120 mg once daily. Intensive blood sampling was performed to assess the PK interaction potential. Assessment of relative BA indicated that exposure to CsA co-administered with FDV was similar to CsA alone. However, the AUC τ,ss and C max,ss of FDV were increased by 23% and 41%, respectively, when FDV was co-administered with CsA. Exposure to TAC was slightly increased (AUC 0-∞ increased by 27%, no change in C max ) when TAC was co-administered with FDV. In contrast, exposure to FDV co-administered with TAC was similar to FDV alone. No unexpected safety findings arose from the trial. The limitations of the study (use of single, low dose of TAC and CsA, and only healthy volunteers in the trial) are discussed.
(© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje